As of March 31, 2020 (median follow-up, 13 days; interquartile range, 2–20 days), 11 patients (39.3%) had died, 1 (3.6%) was still hospitalized in an intensive care unit, and 16 (57.1%) had been discharged. During the COVID-19 outbreak, the regional STEMI network was reorganized, 2 and we have observed a reduction in the number of patients presenting with STEMI. Both factors might have contributed to the relatively low number of cases observed during the study period. However, considering the cardiovascular risk profile of patients with COVID-19, many of these are expected to have STEMI in the coming months. Evidence-based strategies are mandatory to guide their clinical management. Our findings provide relevant evidence showing that, although all patients had a typical STEMI presentation, angiography demonstrated the absence of a culprit lesion in 39.3% of cases, therefore excluding a type 1 myocardial infarction. A recent document from the American College of Cardiology’s Interventional Council and the Society of Cardiovascular Angiography and Intervention discusses how to guarantee state-of-the-art treatment as well as the safety of healthcare providers involved in management of STEMI in the context of a COVID-19 outbreak. 3 The document recommends weighing carefully the balance between healthcare provider exposure and